News | January 31, 2012

ACR Dose Index Registry Reaches Milestones: One Million Scans, 300 Facilities


January 31, 2012 — Since its launch less than a year ago, more than one million computed tomography (CT) scans have been contributed to the American College of Radiology (ACR) Dose Index Registry (DIR) and compiled for analysis. The DIR currently has 326 registered facilities including private practices, hospital-based facilities and academic centers.

Data collected from the DIR — which allows imaging facilities to compare their CT dose indices to regional and national values — is used to establish national benchmarks for CT dose indices to help ensure that patients receive safe, quality imaging care.  

“The tremendous interest and participation we’ve seen to date shows that medical imaging providers are committed to optimizing the radiation dose that their patients receive from CT scans. With one million scans already, we are well on our way to establishing national benchmarks. Those benchmarks will enhance our ability, and that of individual facilities, to track dose reduction efforts over time and ultimately lower the radiation dose that Americans receive from medical imaging scans,” said Richard L. Morin, Ph.D., chair of the ACR Dose Index Registry. 

The DIR is part of the overall ACR approach to medical radiation reduction, which includes mandatory accreditation of all medical imaging providers and greater adoption of computerized decision support/imaging ordering systems based on ACR Appropriateness Criteria. 

For more information: nrdr.acr.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now